Navigation Links
Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
Date:6/2/2008

.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, cardiovascular disease, and other areas of unmet medical need.

This press release contains forward-looking statements, including statements regarding the potential administration, dosing and therapeutic benefit of Clolar in various cancer indications; the expected results of the data generated from the Clolar clinical trials; and the requirements and plans for regulatory filings and approvals for Clolar in additional indications. These risks and uncertainties include, among others, the timing of discussions with the FDA regarding clinical studies and approval of Clolar in additional indications; the timing and content of decisions by the FDA related to clinical trials and approval of Clolar in additional indications; the actual efficacy and safety of Clolar for the indications in which it is being tested; and the risks and uncertainties described in reports filed by Genzyme with the U.S. Securities and Exchange Commission, including without limitation t
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
3. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
4. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
5. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
8. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
9. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
10. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
11. A Functional Immune System Can Be Derived From Embryonic Stem Cells, Preliminary Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015 Dyadic International, ... whose patented and proprietary technologies are used to ... for the bioenergy, bio-based chemical, biopharmaceutical and industrial ... its financial results for quarter ending March 31, ... 2015 and will host a conference call that ...
(Date:5/4/2015)... May 4, 2015 Henry Schein, Inc. (NASDAQ: ... care products and services to office-based dental, animal health ... the quarter ended March 28, 2015. Net ... billion, an increase of 1.4% compared with the first ... local currencies and a 6.0% decline related to foreign ...
(Date:5/4/2015)... May 4, 2015 According to ... Scope (Rigid (Laparoscope, Ureteroscope), Flexible (Colonoscope, Gastroscope), Visualization Systems ... (Colonoscopy, Laparoscopy, Arthroscopy) - Global Forecasts to 2019 ", published ... reach $19.0 Billion by 2019 with a CAGR of ... Browse   127   ma ...
Breaking Medicine Technology:Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 2Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 3Henry Schein Reports Record First Quarter Results 2Henry Schein Reports Record First Quarter Results 3Henry Schein Reports Record First Quarter Results 4Henry Schein Reports Record First Quarter Results 5Henry Schein Reports Record First Quarter Results 6Henry Schein Reports Record First Quarter Results 7Henry Schein Reports Record First Quarter Results 8Henry Schein Reports Record First Quarter Results 9Henry Schein Reports Record First Quarter Results 10Henry Schein Reports Record First Quarter Results 11Henry Schein Reports Record First Quarter Results 12Henry Schein Reports Record First Quarter Results 13Henry Schein Reports Record First Quarter Results 14Henry Schein Reports Record First Quarter Results 15Henry Schein Reports Record First Quarter Results 16Henry Schein Reports Record First Quarter Results 17The Medical Videoscope Market Worth $19.0 Billion by 2019 2The Medical Videoscope Market Worth $19.0 Billion by 2019 3The Medical Videoscope Market Worth $19.0 Billion by 2019 4The Medical Videoscope Market Worth $19.0 Billion by 2019 5
(Date:5/4/2015)... Malibu, CA (PRWEB) May 04, 2015 ... of KissSafe™ oral antiseptic breath spray. KissSafe™ is ... making kissing a safer experience while adding fresh ... that safely and effectively kills germs in the ... kissing. It also contains ingredients that possess additional ...
(Date:5/4/2015)... May 04, 2015 Leonardo J. Lozada, ... chief physician executive, and William C. Daniel, M.D., Saint ... accepted personal invitations from the Secretary of the Air ... (NSF) at the Air War College, Maxwell Air Force ... influential citizens to senior U.S. and international officers and ...
(Date:5/4/2015)... May 04, 2015 The University ... today launched a new initiative at UC Davis ... generation of physicians committed to advancing Latino health. ... Medicos, or Preparing Students to Be Physicians, (“Prep ... will provide scholarships, mentorship and internship opportunities, a ...
(Date:5/4/2015)... 04, 2015 Takeda Pharmaceuticals Corp. has ... settle thousands of Actos lawsuits ( http://www.theactoslawsuitcenter.com/ ) ... risk that a patient will develop bladder cancer. According ... 95% of those eligible for the Actos settlement accept ... cancer cases currently pending in courts around the country, ...
(Date:5/4/2015)... McNeil & Company , a nationwide ... coverage for its Emergency Services Insurance Program ... and proactive risk management to the emergency services industry. ... providing our customers with unparalleled service and the best ... are excited to launch over 100 new enhancements that ...
Breaking Medicine News(10 mins):Health News:80 Million Germs from Kissing - Introducing KissSafe™ 2Health News:Saint Luke’s Health System Leadership Selected to Attend National Security Forum 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 3Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 4Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 5Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3
... Food and Drug Administration (FDA) have approved the drug Femara ... breast cancer among post menopausal women//. ,Various studies ... result of these studies was published in the December 29 ... said that the Novartis drug Femara was very efficient in ...
... of swallows in Malawi had raised fears about the possibility of ... // have revealed a negative bird flu infection status of ... ,"We have tested samples that were sent to us ... swallows, which were dying in large numbers. We don't know what ...
... enterotoxin produced by the bacteria Vibrio cholerae, which leads to ... has occurred in two cities in // ... infected with the bacteria in two districts of Chikomba and ... is high in conditions where treatment is not given. The ...
... in attitudes toward circumcision in Swaziland, which has one of ... one of the highest HIV prevalence rates. ... sudden comeback in the country since the publication of a ... risk of contracting HIV. ,According to the ...
... children is a major health hazard. More-so when homes use ... lead // poisonings in children, by suggesting new requirements ... years, Lead, a highly toxic metal has been used as ... spectrum of health problems ranging from cognitive impairment and learning ...
... Kerr has urged to increase awareness of organ donation among ... loss dying // due to organ failure and non-availability ... heavy human loss of young people and their lives depend ... Donor cards and registration with NHS organ donor register, which ...
Cached Medicine News:Health News:Men queue up for Circumcision In Swaziland To Prevent HIV/AIDS 2Health News:Child-friendly initiative For Lead-Based Paint Work: EPA, USA 2
This standard tying forcep is curved with 5mm titanium coated platforms. Length 85 mm....
Catalano curved tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
Kelman - McPherson tying forceps with serrated handle, platform 4 mm and overall length of 85 mm....
Troutman tying forceps are curved, delicate, bullet shape, with tying platforms. Flat pattern. Ultra fine platforms ideal for 10-0 or 11-0 suture material. Platforms fully meet to hold suture firmly....
Medicine Products: